Pharmacogenetic association studies have the potential to identify variations in DNA sequence which impact drug response. Identifying these DNA variants can help to explain interindividual variability in drug response; this is the first step in personalizing dosing and treatment regimes to a patient's needs. There are many intricacies in the design and analysis of pharmacogenetic association studies, including having adequate power, selecting proper endpoints, detecting and correcting the effects of population stratification, modeling genetic and nongenetic covariates accurately, and validating the results. At this point there are no formal guidelines on the design and analysis of pharmacogenetic studies. The Industry Pharmacogenomics Working Group has initiated discussions regarding potential guidelines for pharmacogenetic study design and analyses (http://i-pwg.org) and the results from these discussions are presented in this paper.
Introduction
The key to the realization of personalized medicine is the ability to identify subgroups of people with an improved risk/benefit profile to a drug or class of drugs allowing for more individualized prescribing. Pharmacogenetics is one tool employed with the goal of achieving this objective. Properly designed and analyzed pharmacogenetic association studies have the potential to improve the discovery, development and ultimately the prescription and clinical usage of drugs by identifying DNA sequence variation that is associated with safety and efficacy of drugs. Although our knowledge of the human genome and how it varies among people has increased dramatically over the past decade, 1, 2 there is still relatively little known about how these genetic differences impact individual response to drugs. 3 This is an essential link needed towards realizing proper dosing and drug choice and thus personalized medicine.
In 2004, the Food and Drug Administration (FDA) published initial guidelines for the submission of genomic data in order to encourage pharmacogenetic research during clinical drug development. In 2006, the International Conference on Harmonization issued a draft consensus guideline, agreed upon by the regulatory authorities of the European Union, Japan and USA, regarding terminology in pharmacogenomics (E15). 4 The E15 guideline defines pharmacogenetics as ' The study of variations in DNA sequence as related to drug response'. This paper, by the Industry Pharmacogenomics Working Group (http://i-pwg.org), focuses on association studies in pharmacogenetics and is intended to supplement these previous documents. Specifically by providing general guidelines relevant to the design and analysis of pharmacogenetic studies, and its application to drug development with the ultimate goal of achieving personalized medicine. Figure 1 illustrates the general approach described in this paper.
Study design
As pharmacogenetic studies are frequently supplemental components to clinical studies, they are not stand-alone protocols designed to investigate the genetic effects related to drug response, which creates challenges for the analysis of pharmacogenetic studies and the interpretation of results. Therefore, pharmacogenetic studies are often case-control association studies looking at patients with and without a certain clinical response and are selected from a cohort being studied for clinical efficacy. Potential biases introduced by these designs must be considered. Unlike traditional genetic studies which investigate disease susceptibility, the drug effect which is essentially an environmental insult, needs to be considered in pharmacogenetic studies.
Study types: hypothesis generating versus hypothesis testing, retrospective versus prospective testing
The first step in a pharmacogenetic study is often determining if the objective is to test a known hypothesis, or a genetic variation that is presumed to be involved in a drug response, or whether the objective is to generate a hypothesis by analyzing the genome more broadly to discover genes associated with a clinical endpoint. Hypothesisgenerating studies focus on discovery of genes and variations that impact a clinical endpoint. As a result, these studies often test large numbers of genes and genetic variants to investigate potential genetic effects. On the other hand, hypothesis-testing studies assess the potential of one or more genetic variants contributing to either drug response or another predefined endpoint. As the biology is hypothesized or known, frequently, the polymorphisms examined are well studied and have known functionality or relationship to functionality. An example of this is study which investigated the association between genetic variation in CYP2C9 and vitamin K epoxide reductase (VKORC1) in patients at risk for thromboembolic events and their response to warfarin dosing. Both genes have known functionality with CYP2C9 involved in warfarin metabolic clearance and VKORC1 encodes the molecular target of warfarin.
Both hypothesis generation and hypothesis-testing studies are often initially conducted in a retrospective manner. That is, as stated above, they are tested in set of samples collected from a study or multiple studies conducted primarily for a different purpose than purely pharmacogenetic investigation. A critical step in determining the clinical utility of any marker, including a genetic marker, is the prospective test of the hypothesis. Before a marker is utilized to stratify patient treatment, it must be tested prospectively. A prospective design may be a prospective hypothesis tested in a retrospective cohort and then confirmed in a second independent sample. An alternative prospective design includes randomization by genotype into the treatment arms without stratification of treatment by genotype. 5 The most complex alternative, is a true prospective randomization study where the clinical response of interest is stratified by genotype. For industry, the intended use of the marker and regulatory implications often guide the design of the prospective test of the hypothesis.
Genome-wide association studies and candidate gene association studies One design consideration for a pharmacogenetic study is how broadly the genome should be interrogated. Genomewide association (GWA) studies test the association between a clinical endpoint and single-nucleotide polymorphisms (SNPs) and/or other types of genetic variation dispersed across the genome. Candidate gene studies test the association between the endpoint and a specific gene or genes with a hypothesized relationship to the endpoint. The warfarin study mentioned above is an example of a candidate gene approach where genes with known biological effects on the drug response were tested. Candidate gene studies may also pursue regions that may be down-or upstream of the actual target and/or genes involved in disease pathophysiology.
Rationale for GWA versus candidate gene
The primary consideration in a GWA or candidate gene approach is the current state of scientific knowledge. If the level of biological understanding permits formulating testable hypotheses with confidence, the researcher will generally employ a candidate gene analysis. Alternatively, if the level of knowledge precludes development of a strong, testable hypothesis, a GWA study may initially be employed to identify genetic variation associated with a phenotype. As GWA have demonstrated, one advantage of this design is finding association with genes, pathways and biology previously not believed to be involved with the phenotype or clinical outcome under study. 6 Other practical factors weighing in on the choice of GWA versus candidate gene include the availability of resources including budget and DNA volume, availability of statistical Figure 1 Summary table of issues to consider when conducting a pharmacogenetic study.
Designing pharmacogenetic projects in industry CM Bromley et al support, and the permission granted in the informed consent document. GWA studies can be costly not only for the genotyping costs but in the generation of enough samples with the requisite clinical data to conduct an adequately sized study. In addition, the data generated are computationally intensive, and often requires more elaborate IT infrastructure and statistical support than a candidate gene study. Also making a GWA resource intense, is that it is typically a hypothesis generating study and additional confirmatory data set(s) are needed. Other practicalities include ethics committee approval, which may be more difficult to obtain for a GWA study than for the more focused investigation of a candidate gene study, especially in the global environment of a typical drug trial.
The advantage of candidate gene studies is the converse. The number of genes and variants examined is flexible and often fewer and thus, the sample sizes needed to achieve adequate power are typically smaller. Therefore, more cohorts may be available to conduct these studies. Selecting the appropriate gene pathways and tagging SNPs can be cumbersome, often requiring more work and resources than conducting a WGA study especially if the candidate gene list is large. One additional advantage is in the coverage of those genes. With a GWA typically the limitation is to interrogate alleles with a relatively high frequency or 'common genetic variation'. In a candidate gene approach the extent to which the genetic variation is interrogated is determined in each case, improving the ability to detect association with a rare variant. Even with a large candidate gene list and comprehensive coverage of the genes, these studies are still limited to known or hypothesized biology, the primary limitation.
Genome wide association studies were initially conducted using all available samples in one step, an all-inclusive onestage study. Confirmation was then considered only when replicated in an independent cohort. However, recently a two-stage design has been proposed. [7] [8] [9] [10] For a two-stage study, all markers are genotyped in a subset of the available samples in stage 1, and based on the results of this stage, selected markers are genotyped and analyzed in the remaining samples (stage 2). The results of stage 2 are treated as an independent study and serve as basis for the final conclusion and a confirmation of the original finding. This allows the statistical significance level and the multiple-testing adjustment (please refer to section below) to be set at the level of the confirmation. 11 The original consideration for a two stage design was to reduce the genotyping costs. In an industry setting other practical considerations; such as the availability of sufficient samples to confirm, may be the primary rationale behind this choice rather than reduction in genotyping costs. For example, often samples are only available from one study and several years, if ever, may be between the initial observation and confirmation. The two-stage design may provide information to either improve or decrease the confidence in the initial observation. Conversely, more recently analyzing one large data set rather than two smaller data sets was advocated. 12 This study demonstrates that analyzing one large data set almost always leads to increase power, despite the need to use a more stringent significance level. Therefore, in chosing which is more appropriate for a specific pharmacogenetic study under design, careful consideration to the overall objectives, strength of data necessary to have a clinically relevant effect, sample availability, critical timing of information, budget availability, and overall cost of the study must be given and will impact the decision regarding what fraction of the total sample size should be used at the initial stage I. Understandably, one would want to use the minimum number of samples to identify the genetic effect while allowing for an appropriately powered confirmatory study as soon as possible in the development timeline. If too small of a sample is investigated, modest but important effects may be missed. Once an effect is missed in the initial stage, it often will not be followed up at the subsequent stages. Clearly, a careful balance must be struck between false positive and false negative rates in the initial studies. When testing a single hypothesis, the false positive or type I error rate (a.k.a. a), is traditionally set to 0.05. This means that there is a 5% chance of a variant with no impact on the clinical endpoint being mistakenly classified as having an impact. Relaxing the type I error rate increases the power of finding a significant result at the expense of increasing the likelihood of a false positive. In GWA studies with a large number of markers, the challenge is to balance this false positive rate and the ability to detect a true effect, power. 13 Power and sample size considerations are discussed in detail in a separate section below.
Selecting genetic polymorphisms and other variation
The human genome contains a lot of variation including SNPs, insertion, deletions and repeated elements such as copy number variants (CNV). Less is known about the other types of variation such as CNV; therefore, selection of what and how to genotype is not as clear. SNPs are currently the most common type of DNA variation genotyped for association studies. Therefore, the following applies to the selection of SNPs.
It has been estimated that the human genome contains approximately 9-10 million SNPs 14, 15 alone. To reduce the number of SNPs that need to be examined, both GWA and candidate gene studies take advantage of patterns of allelic association, also known as linkage disequilibrium (LD). If a set of SNPs is in strong LD, tests of association for a given endpoint will generally produce similar results; hence, a smaller selection of representative SNPs can be examined with only a small possible loss of information. Consequently, even if the causal SNP is unknown or not assayed, a significant association could still be produced by a SNP in strong LD with the causative variation, signaling the region of the genome and/or gene that is associated with the endpoint.
As multiple factors influence LD between SNPs, it's size can vary considerably between genomic regions, ethnic groups and different subjects in the same ethnic group. 16, 17 It is also possible that SNPs that are physically close to each Designing pharmacogenetic projects in industry CM Bromley et al other may be in weak LD, 18 for instance if SNPs are in recombination hotspots, LD would be reduced. The success of a SNP association study depends partially on how well the assayed SNPs 'cover', or 'tag' the putative causal variants.
Two general approaches are often used for choosing tagging SNPs. In the first method, r 2 , a measure of pairwise LD, is examined between all SNPs (or a reasonable subset if dealing with the whole genome). Tagging SNPs are selected such that any non-tagged SNP has an r 2 above or equal to a predetermined LD threshold with at least one of the tagging SNPs. A relatively stringent r 2 threshold (r 2 40.8) will cover over 80% of all haplotypes in a region. 19 Of note is that r 2 or D 0 can be used in the estimation of LD. Whereas D 0 is a measure of the covariance of allele counts for two SNPs, under the assumption of Hardy-Weinberg equilibrium (HWE), r 2 is the measure of Pearson's correlation between the presence of minor alleles for each of two SNPs, also under the assumption of HWE. Note that r 2 take minor allele frequency (MAF) into consideration in its numerator whereas D 0 does not directly take MAF into consideration. The second method requires the haplotype block (i.e., a set of SNPs in relatively strong LD) to be identified using various measures of LD and inferred haplotypes. One or more SNPs from a haplotype will be chosen based on the level of correlation within the haplotype.
For a GWA study, the number of SNPs necessary to adequately tag the putative 9-10 million SNPs in the human genome varies by ethnic group. The current estimate for those of European ancestry is between 300 000 and 600 000 SNPs. For a candidate gene study, tagging SNPs may be selected using genotype data available from the International HapMap Project. 1 In addition, tagging SNPs are often supplemented with variants from the literature or databases, such as dbSNP, 20 hypothesized to be associated with the endpoint.
For a candidate gene study, when the decision has been made to genotype a portion of the gene to test for association rather than sequence the entire gene, different strategies may be employed for variant selection. Although often similar to the above strategy to cover the gene with tags, frequently additional genotyping is completed to test for known functional variants or certain regions of the gene such as exons or regulatory regions with known functional consequences regardless of frequency or LD status.
Selection of phenotypic endpoints
In addition to the proper genotyping choice, the choice of proper endpoints and collection of data on relevant phenotypes for drug response, covariates or confounding factors, are crucial to the success of pharmacogenetic studies. As mentioned before, phenotypic data usually come from a study that was performed for purposes other than a pharmacogenetic analysis and the definitions of endpoints and study population may not be optimal for the purpose of finding genes. Collecting adequate numbers of homogeneous subjects may be problematic if the DNA is sourced from subjects treated with the same drug but from variable situations, either different studies or standards of care.
Parameters will most likely vary among trials such as disease indication, drug dose, drug route of administration, subject age, treatment duration, efficacy or adverse event measurement methods, timing of the measurements of efficacy or adverse events, and study purpose (e.g., early studies examining a pharmacokinetic or phamacodynamic response, or an early study establishing short term efficacy, or studies examining long-term efficacy and safety). Although homogeneous populations are preferable, reasonable differences may need to be chosen, for example, data can be pooled from trials where subjects received a similar dose.
In addition to parameters varying among trials, subjects within trials will differ by epidemiological variables and baseline characteristics such as age, gender and/or severity of disease, among others. When investigating patients from the general health care system receiving the standard of care, the phenotype may be even more diverse. Although it is possible that subjects may differ so much that using only a subset is reasonable, usually adjustments for these differences can be performed statistically.
Another factor influencing the heterogeneity of available phenotypic data is the phase of development of the molecule. Is it pre-or post-regulatory approval? The traditional path toward regulatory approval involves small studies investigating pharmacokinetic and pharmacodynamic effects of the medication, with the final progression to a large trial measuring clinical efficacy and safety using the gold standard clinical outcome measure. The stage of the progression of the molecule influences not only the type of available clinical data but also the timing of availability of that data. If multiple large phase III trial clinical data and associate samples are not available, a combination of other clinical measures may be necessitated.
Even when clinical outcome is measured, a cluster of related endpoints may be pooled together in the analysis to increase the number of subjects in each category. For example, when studying a cardiovascular disease, investigators focused on primary outcomes (1) cardiovascular death, nonfatal MI, or stroke and (2) outcome 1 or refractory ischemia. 21 However, metabolic syndrome is a common risk factor for both stroke and heart disease, 22 so it seems reasonable to assume that they share some common underlying biological mechanisms. Therefore, reclassifying the combined cardiovascular death, heart disease and stroke as a 'cardiovascular disease-related endpoint' in the analysis may make sense. 23 In other situations, the definition of the endpoint may be broad and encompass events that differ mechanistically. Appropriately narrowing or broadening the definition of an endpoint is frequently beyond the expertize of a geneticist or statistician and will require input from a clinical specialist. When defining the clinical phenotype the question and information of interest is paramount. If it is known that a specific response relates to an underlying physiological effect, the collection of both clinical and laboratory measures that relate to this response could aid in validating genetic effects.
When designing a pharmacogenetic study, the complexities discussed needs to be kept in mind and carefully considered when calculating effect size and power and ultimately during interpretation of results.
Power and sample size determination Power is the ability of the study to correctly detect variants that are associated with the endpoint. The type II error rate (a.k.a. false negative rate) is the chance that variations with an impact on the endpoint will not be detected. The power is equal to one minus the type II error rate. Traditionally 80% power is considered sufficient; thus the type II error rate will be 20%. Power is the probability of detecting a significant effect in a particular research setting, given that an association exists. Multiple factors that determine the power including sample size, gene effect size, MAF, mode of inheritance and the false positive rate (Figure 2 ).
An important concern for sample size is not only the size of the relevant genetic effect, but also the size of the expected drug response. These two effects in concert determine the clinical relevance of an identified effect. It is important to assess the required sample size at the beginning of study planning considering all factors including the choice of the endpoint and the selected statistical approach.
If the pharmacogenetic study is part of a core clinical trial and sample size is determined by the primary objectives of the trial. In this setting, power for the pharmacogenetic study can be assessed based on given sample size of subjects who have both genotypic and phenotypic data. If a pharmacogenetic study is a primary objective and planned de novo, the sample size needed to discover the relevant genetic effect should be calculated prospectively and carefully considered before implementation.
Pharmacogenetic studies have a high probability of false positive results when large numbers of SNPs are analyzed. When only a few polymorphisms are tested in a hypothesis driven order, setting the type I error rate near 0.05 as each comparison is tested may be acceptable. In larger scale candidate gene studies and whole genome screens, a large number of false positives will be identified if a false positive rate of 0.05 is used when testing each polymorphism. For example in a study of 10 000 independent SNPs, an expectation at 0.05 would be to find 500 false associations. The lower the P-value needed to determine significance the more samples required.
As mentioned previously, multiple factors influence the power including the MAF of the associated variant. A lower MAF corresponds to a lower power. This is highlighted in Tables 1 and 2 which demonstrate the sample size needed to obtain an 80% power for either an additive trait in a one to For relatively uncommon alleles (MAF o0.10), the required sample sizes could be quite large. Therefore, before implementation of the study, understanding the relationship between MAFs, sample size and the effect size to understanding the power for the study (for this example power ¼ 80%) is critical. Genetic associations with large effect size are easier to detect; therefore, effect size (and confidence bounds) should be taken into account when evaluating the statistical feasibility of pharmacogenetic studies. Large differences between response groups or large differences in means would reduce required sample size. Also, efficacy could differ within subpopulations in studies which consider several populations. Small differences in efficacy may be true in a larger population, but these same differences could be large within a subpopulation. This was the case with rosiglitazone in a phase II study in Alzheimer's disease. When the whole study population was included, no statistically significant differences were detected on primary endpoints between placebo and any rosiglitazone dose. However, when analyses were limited to the negative apolipoprotein E (APOE)-e-4 subpopulation, statistically significant differences in response to the drug were detected. 24 The precedence for labeling a drug for a subpopulation is already established by drugs such as Herceptin, for breast cancer patients with human epidermal growth factor receptor 2 amplification, and Bidil, labeled for African-American subjects with heart failure.
The larger the effect size between the gene and the clinical endpoint, the smaller the sample size needed. 25 For example, in Table 1 , within a given MAF, as the odds ratio increases, the sample size needed to achieve 80% power decreases drastically. 26 Given that the strength of the effect is important to power and sample size, it is important to obtain a plausible estimate of the effect. Although there is no simple answer on how to do this (as the estimate of the effect varies from situation to situation), there are ways to estimate the effect before beginning the study. In a smallscale candidate gene study where genes are examined based on their known impact on drug response (either for the drug under study or a similar drug), results from prior pharmacogenetic analyses of the gene may be available. For example, the APOE study cited above that examined genotype and treatment response could be used as an estimate before the initiation of a candidate gene study. When an estimate of the effect size is not available, as an alternative the study may simply be powered to detect the effect size that is determined to be relevant or that desired to be discovered.
Another consideration in effect size is the distance and/or LD between SNPs that are genotyped. Although SNPs in LD may not be physically close together on the chromosome, the denser the SNP map, the more likely that one of the SNPs will be in high LD with the causative locus. If a marker and the unknown causative locus are not in perfect LD, sample size needed to achieve the same power as a direct method is inversely proportional to r 2 . 27 For example, with an r 2 of 0.5, the sample size based on a marker SNP will be two times higher than would be needed if the 'causative locus' itself was genotyped, which may be too large to be practical.
With a GWA study, the large number of SNPs required to cover the genome, necessitates a large number of statistical tests; thus, greatly raising the threshold for statistical significance. Consequently unless the impact of the associated variant on the clinical outcome is very large, many samples are required to achieve results considered statistically significant (see below). Therefore, another practical consideration in choosing a GWA versus a candidate gene design is the number of samples available for testing.
Statistical analyses
Pharmacogenetic analyses are frequently performed similar to other statistical analyses using traditional tools (e.g., linear or logistic regression, survival analysis). Some of the same considerations of traditional statistical analyses apply to statistical analyses of pharmacogenetic data and include: which covariates to include in the model; what type of modeling approach to use (continuous, binary, categorical or time-to-event); whether to transform covariates or endpoints to improve the fit of the model or to ensure that the underlying assumptions behind the statistical test hold and the P-values are valid; whether to test for significance using a nonparametric, permutation or bootstrapping approach if the underlying assumptions do not hold. Discussion of these common statistical analyses and issues can be found from various resources.
28-34
Quality control of data To ensure accuracy of the model, the genotypic and phenotypic data must be cleaned before entering the model. It is important to verify the quality of genotypic and phenotypic information before analysis because poor quality data can lead to identification of spurious results or mask potential real effects.
Genotypic data quality checks include: cross-checking data provided by assay vendor against known databases (e.g., National Center for Biotechnology Information, http://www.ncbi.nlm.nih.gov/); identifying patterns of missing genotypes or low call rates (e.g., within subpopulations such as older studies, within specific ethnicities or within some individuals); examining deviations from HWE within cases or controls (deviation could be due to either true genetic effects, genotyping error or population stratification). Also, carefully examined patterns of missing values in GWA studies may help on deciding what imputation methodology is to be used. 35 As spurious phenotypic data can lead to misleading results or mask potential genetic effects, it is important to summarize continuous phenotypic endpoints separately for cases, controls or other subgroups by mean, median, minimum, maximum, missing values, skewness and kurtosis. If normality does not hold, one may transform or categorize the phenotype for better modeling. Categorical endpoints can be summarized for case-control studies by frequency for each genotype within a SNP.
Selecting covariates and building a model
After selecting the type of model and cleaning the genotypic and phenotypic data, the variables should be tested for an association in a univariate model. It is important to test the individual effects before putting them in a multivariate model as a large number of genetic and nongenetic variables may affect pharmacogenetic response models.
There are multiple ways to model non-genetic variables, for example, age can be modeled as a continuous variable or split into categories based on biological or clinical relevance. If a variable is categorized, it can either be put into a multivariate model as an effect modifier or the data can be stratified by that variable and each group modeled separately.
When selecting significant covariates from the univariate models, it is important to consider statistical significance, biological meaning and clinical relevance. It is also prudent to include significant effects in a multivariate model and test for potential interactions between effects that are included. Missing observations require caution, as logistic regression analyses do not include missing observations. This could lead to a reduced number of observations in the model. Either genotypic and/or phenotypic missing observations may not be due to random effects and cause bias in interpretation of results if not considered carefully.
The mode of inheritance must also be considered when modeling genetic variables. A SNP can be modeled categorically as genotypic, or as dominant or recessive by combining groups of genotypes. It could also be considered additive by modeling it as an ordinal variable.
Analyzing gene by gene and gene by environment interactions
After examining each polymorphism, it is important to test whether the genes interact with each other or with environmental covariates. Interpreting the results can be difficult due to the large number of combinations possible when investigating thousands of polymorphisms. Triaging will help: rather than examining all possible combinations, initially focus on interactions involving the genes or polymorphisms that were significant alone, and then examining combinations with all other genes or polymorphisms. Alternatively, combinations only of genes involved in the same pathways, should be examined. 36 Population considerations Stratification/population substructure. Various authors have raised concerns that designs using unrelated individuals may suffer from a form of confounding known in the genetics literature as population stratification. [37] [38] [39] Confounding occurs when the population under study consists of genetically different subpopulations (e.g. ethnic groups) and individuals are selected from the subpopulations in different proportions in cases and controls. As allele frequencies and disease rates can differ significantly between major ethnic groups, [39] [40] [41] population stratification may increase the false positive rate and mask real effects. 39, 40 The extent and impact of subtler forms of genetic substructure that may exist within ethnic groups is largely unknown, although Marchini et al. 40 found that even slight genetic substructure could have deleterious effects on a study. To minimize genetic variation that is unrelated to the trait of interest, cases and controls need to be ethnically matched or adjusted for in the statistical analysis. In practice, it is usually only possible to match crudely (e.g., Caucasian cases versus Caucasian controls), and it is strongly advised that the cohort be assessed to verify that any associations do not result from population substructure. Instead of using selfidentified ethnicities, statistical models to assess individuals' ethnic origins based on their observed genotypes have recently been developed. For example, the genomic control method proposed by Devlin and Roeder 42 uses a set of null markers (markers unlikely to affect liability) to determine the appropriate correction factor for population-based association tests. The 'structure association' approach outlined by Pritchard et al. 43, 44 utilizes genotypes at multiple unlinked loci to assign individuals to K populations (K may be unknown) probabilistically. An individual may be assigned to one, or jointly to two or more populations, if their genotypes suggest admixture. The estimated individuals' origins can then serve as covariates for subsequent analyses to avoid potential confounding caused by population substructure.
More recently, Price et al. 45 developed a principal components approach that utilizes the covariance matrix of the genotypes to infer individuals' continuous axes of genetic variation. Another recent paper by Epstein et al. 46 described a two-stage method that incorporates the phenotype information in ancestry inference. In the first stage, they model the odds of the disease using genotypes as ancestry informative markers and generate a stratification score for each individual. In the second stage, they assign individuals to strata according to their stratification scores and test for association with adjustment for these strata.
Another potential source of confounding in case-control studies is caused by the heterogeneity in clinical data. Because a single response phenotype could be produced by multiple different genotypes, subtle clinical differences may help to select cases that most resemble each other in order to enrich for subjects with the same underlying genotype. In genetic association studies, the trait of interest must have genetic basis and the DNA samples comprising the cases and controls must be well matched and linked to richly detailed clinical data. Because an apparent discovered association could be an artifact of confounding, once an association is discovered, it is necessary to replicate the result in an independent population.
When designing pharmacogenetic studies, care needs to be taken to avoid potential ascertainment bias that could result from excluding patients with specific genetic backgrounds. Possible sources of bias include low participation of certain ethnic groups, patients who are not captured into the study due to early drop out induced by adverse events and patients who are not included based on certain inclusion or exclusion criteria. It is, therefore, important for the study team to carefully consider potential sources of bias that could be introduced through the study design.
Multiple comparison and validation. Pharmacogenetic studies have a high probability of false positive results when large numbers of SNPs are analyzed. When only a few polymorphisms are tested, setting the experimentwise error rate to 0.05 as each comparison is tested may be acceptable. In larger scale candidate gene studies and whole genome screens, a large number of false positives will be identified if a false positive rate of 0.05 is used when testing each polymorphism. To reduce the number of misclassified SNPs, the comparisonwise error rate can be modified. An exhaustive description of the types of adjustments and their rationale is beyond the scope of this paper. We briefly describe some common adjustments used in statistical genetics.
Bonferroni: Rather than setting the false positive rate on a comparison-by-comparison basis, the false positive rate can be set for the experiment overall. In a Bonferroni adjustment, the false positive rate for each comparison is modified to 0.05/h, where h is the number of hypothesis tests being performed within the project. For the experiment overall, the false positive rate will be no larger than 0.05; the probability that one concludes that 'something in the project' had an impact when nothing actually does, will be 5%. For large-scale projects (e.g. genome screens), the comparisonwise false positive rate will be forced down to extremely low levels, greatly increasing the sample size needed to achieve a given power. In addition, the Bonferroni adjustment assumes that the hypothesis tests are not correlated. This is unlikely given that extensive LD exists within the genome; thus, overcorrection for the number of comparisons is likely.
False discovery rate: This approach controls the expected proportion of false positive rate in a set of rejected null hypotheses. The method of controls the false discovery rate, whereas Storey's 48 method estimates it.
Permutation: This approach uses permutations to correct each P-value independently. After P-values are calculated for the original data set, a pseudo-data set is created by randomly dividing the data into response and nonresponse groups and the analysis is then repeated to compute P-values using the new data set. This process is repeated many times, and the minimum P-value from the original data is compared to the distribution of minimum P-values obtained from the permuted datasets. The proportion of permuted P-values that are less than the minimum P-value from the original data is the adjusted P-value. Depending on computational power, this method may take a considerable time to run.
The next important factor after finding an association and determining that the effect is sufficient to possibly have clinical relevance, is to consider sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) as well as prevalence when evaluating pharmacogenetic makers. Table 3 summarizes these criteria. The minimum evidence needed when considering any of these values is no different than for any other biomarker and depends on whether response is considered for efficacy or toxicity. Other factors influencing the acceptability of a marker in clinical practice includes what the intended practice will be clinically. For example will the marker be used to adjust dose to slightly improve efficacy, guide treatment or drug choice, or avoid a side effect. Multiple other factors influence the decision here include the severity of the illness under treatment, the severity of the clinical effect influenced by the genetic marker, and the current state of clinical practice including what alternatives are available. 49 After weighing all of these factors, next steps are determined. If the findings have not been replicated, the obvious first step is a replication. However, the design of that replication (Figure 1) will be influenced by all of these factors.
Conclusion
A great deal of debate centers on the lack of replication of pharmacogenetic findings. Some significant findings may be false positives, whereas others may be true only for the specific population studied. Conversely, others may be false negative with true signals missed due to small sample size or effect size, and/or heterogeneity of the population studied. Owing to inherent complexities, pharmacogenetic studies must be designed and analyzed with caution. Key issues to consider when designing a pharmacogenetic study include: a compelling study design which incorporates selection of proper clinical endpoints, careful phenotypic quality control and statistical considerations consisting of power, detection of population stratification and corrective measures, proper modeling of covariates and genetic variants, validation of results using independent data set(s), and phenotypic and the genotyping data quality itself. When properly designed and analyzed pharmacogenetic markers will provide some of the tools to better understanding of drug response, efficacy and toxicity, and ultimately to better prescribing practices and patient care. Designing pharmacogenetic projects in industry CM Bromley et al
